Topline Results from First Phase 3 Trial of pSivida’s Medidur™ Presented at ASRS Annual Meeting WATERTOWN, Mass., Aug. 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases,...